MedTrace Logo

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

NCT04313634 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-07-22

Study results available
· View outcomes & findings →

Summary

To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.

Conditions

  • Healthy

Interventions

DRUG

Dasatinib

Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated

DRUG

Quercetin

Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg

DRUG

Fisetin

Fisetin will be supplied in 100 mg capsules to be administered orally

Sponsors & Collaborators

  • Sundeep Khosla, M.D.

    lead OTHER

Principal Investigators

  • Sundeep Khosla, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-09
Primary Completion
2023-06-06
Completion
2023-06-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04313634 on ClinicalTrials.gov